Amplified Natural Killer (ANK) therapy is modified to increase the safety and efficacy of the original (LAK) immunotherapy. It is a method of removing natural killer (NK) cells from the patient's own blood, culturing and amplifying the NK cells, specifically increasing their ability to attack cancer and returning them for treatment. It is generally effective against all cancers. The two cases presented here and the other treated cases show that ANK therapy is very safe and effective against ATL. Further research suggests that ANK therapy, rather than chemotherapy, is likely to be the first-line therapy for ATL. In addition, low activity of NK cells means accumulation of bacterial load. Therefore, ANK therapy with high doses of activated NK cells may be effective not only for ATL and cancer, but also for patients with chronic bacterial and viral infections.
Keywords: Adult T-cell leukemia; Amplified natural killer cell therapy; HTLV-1-Associated branching bronchioalveolar disorder; Lymphokine-activated killer cell immunotherapy.